<DOC>
	<DOC>NCT01697072</DOC>
	<brief_summary>This is a phase 3, multicenter, randomized, double-blind, placebo controlled study of epirubicin, cisplatin &amp; capecitabine (ECX) with rilotumumab or placebo for untreated advanced MET-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma</brief_summary>
	<brief_title>First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Key Pathologically confirmed unresectable locally advanced or metastatic gastric or GEJ adenocarcinoma •Eastern Cooperative Oncology Group (ECOG) performance status (0 or 1) Tumor METpositive by immunohistochemistry (IHC) Evaluable (measurable or nonmeasurable) disease by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria Key exclusion criteria: Human Epidermal Growth Factor Receptor 2 (HER2) overexpressing locally advanced or metastatic gastric or GEJ adenocarcinoma •Previous systemic therapy for locally advanced or metastatic gastric or GEJ adenocarcinoma Less than 6 months have elapsed from completion of prior neoadjuvant or adjuvant chemotherapy or chemoradiotherapy to randomization Previous treatment with anthracyclines must not exceed total cumulative dose of epirubicin of 400 mg/m2 Squamous cell histology Left ventricular ejection fraction (LVEF) &lt; 50%</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Gastric Cancer</keyword>
	<keyword>First Line Treatment Gastroesophageal Junction (GEJ)</keyword>
	<keyword>Gastroesophageal Junction Cancer (GEJ)</keyword>
	<keyword>GEJ Cancer</keyword>
</DOC>